AIkido Pharma Executes Licensing Agreement with University of Maryland for Antiviral Compounds, Including COVID-19
NEW YORK, April 21, 2020 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announcedthat on April 13, 2020, the Company executed a Master License Agreement (the "License Agreement") with the University of Maryland, Baltimore ("UMB").
- NEW YORK, April 21, 2020 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announcedthat on April 13, 2020, the Company executed a Master License Agreement (the "License Agreement") with the University of Maryland, Baltimore ("UMB").
- The compounds seek to inhibit replication of multiple viruses, including Influenza virus, SARS-CoV, MERS-CoV, Ebolavirus and Marburg virus.
- The technology is covered by two patent applications already on file with the United States Patent and Trademark Office.
- Mr. Anthony Hayes, CEO of AIkido, stated, "We are excited to move forward with this new antiviral platform.